Our review reports a pooled analysis of chemo-ICI versus chemotherapy in the first-line ES-SCLC setting and is the first to assess the differential efficacy of CTLA-4 inhibitors and PD-1/PD-L1 inhibitors. The gene discussed is CTLA4; the disease is small cell lung carcinoma.